CSI Announces First Treatments in United States With OrbusNeich Teleport Microcatheter
January 9, 2019—Cardiovascular Systems, Inc. (CSI) announced that the first patients in the United States were treated using the OrbusNeich Teleport microcatheter, which recently received FDA 510(k) clearance. In the United States, the Teleport device is indicated for supporting and facilitating the placement of guidewires and exchanging guidewires in the peripheral and coronary vasculature, as well as the delivery of contrast media into the peripheral, abdominal, and coronary vasculature.
According to CSI, Teleport is a new-generation microcatheter designed for deliverability and support, with a tip designed to enable access in the most challenging lesions during complex cardiovascular procedures. In January 2018, CSI announced that it was the exclusive United States distributor for OrbusNeich balloon products.
Annapoorna S. Kini, MD, and Emmanouil Brilakis, MD, treated the first patients in the United States with Teleport.
In the company's announcement, Dr. Kini commented, “I am excited and honored to be the first to use Teleport microcatheter in the United States. Teleport allowed me to deliver the microcatheter easily through tortuous coronary vasculature while maintaining catheter position for guidewire exchange treating a complex chronic total occlusion.” Dr. Kini is Director of the Cardiac Catheterization Laboratory at Mount Sinai Medical Center in New York, NY.
Dr. Brilakis added, “I had the opportunity to use the Teleport microcatheter in Europe and was impressed by its balance of deliverability and support. Teleport’s robust tip design is unique, enabling access to tight lesions while providing the torqueability necessary to treat very challenging lesions. I’m excited to have this device available to treat my patients here in the United States.” Dr. Brilakis is an interventional cardiologist at Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, MN.